

Subject Index

- ADCC**, Herpes simplex virus, HSV glycoprotein, 279
- Acyclovir**, Herpes simplex virus, Guinea pig skin, Antiherpetic substance, Pyrophosphate analogue, 99
- Acyclovir**, Microencapsulated anti-viral assay in mice, Herpes simplex virus, 179
- Adenovirus**, Herpes simplex virus, Cytomegalovirus, Retrovirus, Pyrrolopyrimidine nucleoside, 263
- Anti-HIV compound**, Chinese herb, Polysaccharide, Purification, Chromatography, Spectroscopy, 107
- Antiherpetic substance**, Herpes simplex virus, Guinea pig skin, Pyrophosphate analogue, Acyclovir, 99
- Antiviral treatment**, Coxsackievirus, Lymphocyte subpopulation, Monoclonal antibody, Myocarditis, 129
- Bovine**, Tumor necrosis factor, Interferon, 71
- Castanospermine**, Cytomegalovirus, Glycoprotein complex, Inhibitor, glycoprotein processing enzyme, Deoxynojirimycin, 11
- Cephalosporin derivative**, DNA virus, 59
- Chinese herb**, Polysaccharide, Anti-HIV compound, Purification, Chromatography, Spectroscopy, 107
- Chromatography**, Chinese herb, Polysaccharide, Anti-HIV compound, Purification, Spectroscopy, 107
- Coxsackievirus**, Antiviral treatment, Lymphocyte subpopulation, Monoclonal antibody, Myocarditis, 129
- Cytomegalovirus**, Glycoprotein complex, Inhibitor, glycoprotein processing enzyme, Castanospermine, Deoxynojirimycin, 11
- Cytomegalovirus**, Herpes simplex virus, Adenovirus, Retrovirus, Pyrrolopyrimidine nucleoside, 263
- DNA synthesis**, 2'-Fluoro-5-substituted-ara-pyrimidine, Herpes simplex virus, Incorporation, Metabolism, Selective inhibition, 153
- DNA virus**, Cephalosporin derivative, 59
- 3-Deazauridine**, Immunofluorescence antiviral assay, Pichinde virus, Ribavirin derivative, (S)-9-(2,3-dihydroxypropyl)adenine, 89
- Deoxynojirimycin**, Cytomegalovirus, Glycoprotein complex, Inhibitor, glycoprotein processing enzyme, Castanospermine, 11
- (S)-9-(2,3-dihydroxypropyl)adenine**, Immunofluorescence antiviral assay, Pichinde virus, Ribavirin derivative, 3-Deazauridine, 89
- Enviroxime**, Synergy, Interferon α , Rhinovirus, Prophylaxis, 141
- 2'-Fluoro-5-substituted-ara-pyrimidine**, herpes simplex virus, Incorporation, Metabolism, Selective inhibition, DNA synthesis, 153
- Genital wart**, Interferon α -n1, Human papillomavirus, 41
- Glycoprotein complex**, Cytomegalovirus, Inhibitor, glycoprotein processing enzyme, Castanospermine, Deoxynojirimycin, 11
- Glycoprotein**, Immunotherapy, Recurrent genital herpes, 83
- Glycyrrhizin**, Human immunodeficiency virus, Protein kinase C, Virus adsorption, 289
- Guinea pig skin**, Herpes simplex virus, Antiherpetic substance, Pyrophosphate analogue, Acyclovir, 99
- (R,S)-HPMPG**, Herpesvirus, 235
- HSV glycoprotein**, Herpes simplex virus, ADCC, 279
- HSV-2 infection**, R-837, 209
- Herpes simplex virus**, 2'-Fluoro-5-substituted-ara-pyrimidine, Incorporation, Metabolism, Selective inhibition, DNA synthesis, 153
- Herpes simplex virus**, Microencapsulated anti-viral assay in mice, Acyclovir, 179
- Herpes simplex virus**, Cytomegalovirus, Adenovirus, Retrovirus, Pyrrolopyrimidine nucleoside, 263
- Herpes simplex virus**, ADCC, HSV glycoprotein, 279
- Herpes simplex virus**, OK-432, Immunomodulator, Immunosuppressed mice, 299
- Herpesvirus**, (R,S)-HPMPG, 235
- Human immunodeficiency virus**, Glycyrrhizin, Protein kinase C, Virus adsorption, 289
- Human papillomavirus**, Interferon α -n1, Genital wart, 41

- IFN- γ** , TNF, Potentiation, 1
- rIFN- α Con1**, Intranasal toxicity, 225
- Immunofluorescence antiviral assay**, Pichinde virus, Ribavirin derivative, 3-Deazauridine, (S)-9-(2,3-dihydroxypropyl)adenine, 89
- Immunomodulator**, OK-432, Herpes simplex virus, Immunosuppressed mice, 299
- Immunosuppressed mice**, OK-432, Immunomodulator, Herpes simplex virus, 299
- Immunotherapy**, Glycoprotein, Recurrent genital herpes, 83
- In vivo efficacy**, Murine cytomegalovirus, Interferon- γ , Mortality prophylaxis, 27
- Incorporation**, 2'-Fluoro-5-substituted-ara-pyrimidine, Herpes simplex virus, Metabolism, Selective inhibition, DNA synthesis, 153
- Inhibitor**, glycoprotein processing enzyme, Cytomegalovirus, Glycoprotein complex, Castanospermine, Deoxynojirimycin, 11
- Interferon- γ** , Murine cytomegalovirus, In vivo efficacy, Mortality, Prophylaxis, 27
- Interferon alpha-n1**, Genital wart, Human papillomavirus, 41
- Interferon**, Bovine, tumor necrosis factor, 71
- Interferon α** , Synergy, Enviroxime, Rhinovirus, Prophylaxis, 141
- Interferon-inducing activity**, Lipid A analog, Vaccinia virus, 167
- Intranasal toxicity**, rIFN- α Con1, 225
- Isoflavan**, Rhinovirus 1B, Isoflavene, 117
- Isoflavene**, Rhinovirus 1B, Isoflavan, 117
- Lipid A analog**, Vaccinia virus, Interferon-inducing activity, 167
- Lymphocyte subpopulation**, Coxsackievirus, Antiviral treatment, Monoclonal antibody, Myocarditis, 129
- Metabolism**, 2'-Fluoro-5-substituted-ara-pyrimidine, Herpes simplex virus, Incorporation, Selective inhibition, DNA synthesis, 153
- Microencapsulated anti-viral assay in mice**, Herpes simplex virus, Acyclovir, 179
- Monoclonal antibody**, Coxsackievirus, Antiviral treatment, Lymphocyte subpopulation, Myocarditis, 129
- Mortality**, Murine cytomegalovirus, Interferon- γ , In vivo efficacy, Prophylaxis, 27
- Murine cytomegalovirus**, Interferon- γ , In vivo efficacy, Mortality, Prophylaxis, 27
- Myocarditis**, Coxsackievirus, Antiviral treatment, Lymphocyte subpopulation, Monoclonal antibody, 129
- OK-432**, Immunomodulator, Herpes simplex virus, Immunosuppressed mice, 299
- Phlebovirus**, Ribamidine, Punta Toro virus, Ribavirin, 193
- Pichinde virus**, Immunofluorescence antiviral assay, Ribavirin derivative, 3-Deazauridine, (S)-9-(2,3-dihydroxypropyl)adenine, 89
- Polysaccharide**, Chinese herb, Anti-HIV, compound, Purification, Chromatography, Spectroscopy, 107
- Potentiation**, TNF, IFN- γ , 1
- Prophylaxis**, Murine cytomegalovirus, Interferon- γ , In vivo efficacy, Mortality, 27
- Prophylaxis**, Synergy, Interferon α , Enviroxime, Rhinovirus, 141
- Protein kinase C**, Glycyrrhizin, Human immunodeficiency virus, Virus adsorption, 289
- Protein synthesis inhibition**, Ribavirin nucleotide analog, 253
- Punta Toro virus**, Ribamidine, Phlebovirus, Ribavirin, 193
- Purification**, Chinese herb, Polysaccharide, Anti-HIV compound, Chromatography, Spectroscopy, 107
- Pyrophosphate analogue**, Herpes simplex virus, Guinea pig skin, Antiherpetic substance, Acyclovir, 99
- Pyrrolopyrimidine nucleoside**, Herpes simplex virus, Cytomegalovirus, Adenovirus, Retrovirus, 263
- R-837**, HSV-2 infection, 209
- Recurrent genital herpes**, Glycoprotein, Immunotherapy, 83
- Retrovirus**, Herpes simplex virus, Cytomegalovirus, Adenovirus, Pyrrolopyrimidine nucleoside, 263
- Rhinovirus 1B**, Isoflavan, Isoflavene, 117
- Rhinovirus**, Synergy, Interferon α , Enviroxime, Prophylaxis, 141
- Ribavirin derivative**, Immunofluorescence antiviral assay, Pichinde virus, 3-Deazauridine, (S)-9-(2,3-dihydroxypropyl)adenine, 89
- Ribavirin nucleotide analog**, Protein synthesis inhibition, 253
- Ribavirin**, Ribamidine, Phlebovirus, Punta Toro virus, 193
- Selective inhibition**, 2'-Fluoro-5-substituted-ara-pyrimidine, Herpes simplex virus, Incorporation, Metabolism, DNA synthesis, 153
- Spectroscopy**, Chinese herb, Polysaccharide, Anti-HIV compound, Purification, Chromatography, 107

Synergy, Interferon α , Enviroxime, Rhinovirus,
Prophylaxis, 141

TNF, IFN- γ , Potentiation, 1

Tumor necrosis factor, Bovine, Interferon, 71

Vaccinia virus, Lipid A analog, Interferon-induc-
ing activity, 167

Virus adsorption, Glycyrrhizin, Human immuno-
deficiency virus, Protein kinase C, 289

Author Index

- Al-Nakib, W., see Higgins, P.G., 141
 Alaghamandan, H.A., see Smee, D.F., 253
 Alaghamandan, H.A., see Smee, D.F., 263
 Anderson, K.P., see Fennie, E.H., 27
 Atchison, R.W., see Li, X.Q., 179
- Baba, M., see Ito, M., 289
 Babiuk, L.A., see Campos, M., 71
 Barnard, D.K., see Sidwell, R.W., 193
 Barnett, B.B., see Burns, III, N.J., 89
 Barrow, G.I., see Higgins, P.G., 141
 Bernstein, D.I., Loo, L.S. and Kohl, S.
 Antibody to cloned HSV glycoproteins B and D plus adult human leukocytes protect neonatal mice from lethal HSV infection, 279
 Bernstein, D.I., see Harrison, C.J., 209
 Bernstein, D.I., see Myers, M.G., 83
 Bielefeldt Ohmann, H., see Campos, M., 71
 Bonnez, W., see Reichman, R.C., 41
 Burns, III, N.J., Barnett, B.B., Huffman, J.H., Dawson, M.I., Sidwell, R.W., De Clercq, E. and Kende M.
 A newly developed immunofluorescent assay for determining the Pichinde virus-inhibitory effects of selected nucleoside analogues, 89
- Campos, M., Bielefeldt Ohmann, H., Hughes, G., Babiuk, L.A. and Lawman, M.J.P.
 Studies on the *in vitro* biological activities of recombinant bovine tumor necrosis factor (rBoTNF) alpha. I. Synergistic antiviral efficacy of rBoTNF alpha, recombinant bovine interferon gamma (rBoIFN gamma) and their combination, 71
 Chang, R.S., see Ngan, F., 107
 Chou, T.-C., see Kong, X.-B., 153
 Conti, C., Orsi, N. and Stein, M.L.
 Effect of isoflavans and isoflavones on rhinovirus 1B and its replication in HeLa cells, 117
 Coppenhaver, D.H., see Hughes, T.K., 1
 Cottagnoud, P., Neftel, K.A., Hany, M. and Zinkernagel, R.M.
 Inhibition of HSV-1 and vaccinia virus replication by cephalosporin derivatives, 59
- Dawson, M.I., see Burns, III, N.J., 89
 De Clercq, E., see Burns, III, N.J., 89
 De Clercq, E., see Ito, M., 289
 DeLong, D.C., see Higgins, P.G., 141
- Fanucchi, M.P., see Kong, X.-B., 153
 Farrar, G.H., see Taylor, D.L., 11
- Feldman, A., see Terry, B.J., 235
 Fellows, L.E., see Taylor, D.L., 11
 Fennie, E.H., Lie, Y.S., Low, M.-A.L., Gribbling, P. and Anderson, K.P.
 Reduced mortality in murine cytomegalovirus infected mice following prophylactic murine interferon- γ treatment, 27
 Field, A.K., see Terry, B.J., 235
 Fohlman, J., see Ilbäck, N.-G., 129
 Fox, J.J., see Kong, X.-B., 153
 Frank, K.B., see Smee, D.F., 263
 Friman, G., see Ilbäck, N.-G., 129
- Gall, S.A., see Reichman, R.C., 41
 Gorelik, E., see Li, X.Q., 179
 Gribbling, P., see Fennie, E.H., 27
- Haffey, M.L., see Terry, B.J., 235
 Hagen, M., see Terry, B.J., 235
 Hany, M., see Cottagnoud, P., 59
 Harrison, C.J., Jenski, L., Voychevski, T. and Bernstein, D.I.
 Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection, 209
 Harrison, C.J., see Myers, M.G., 83
 Hasegawa, A., see Ikeda, S., 167
 Hayden, F.G., Innes, Jr., D.J., Mills, S.E. and Levine, P.A.
 Intranasal tolerance and histopathologic effects of a novel synthetic interferon, rIFN- α Con1, 225
 Helbig, B., see Wutzler, P., 99
 Higgins, P.G., Barrow, G.I., Al-Nakib, W., Tyrrell, D.A.J., DeLong, D.C. and Lennox-Smith, I.
 Failure to demonstrate synergy between interferon- α and a synthetic antiviral, enviroxime, in rhinovirus infection in volunteers, 141
 Hirabayashi, K., see Ito, M., 289
 Ho, M., see Li, X.Q., 179
 Homma, J.Y., see Ikeda, S., 167
 Huffman, J.H., see Burns, III, N.J., 89
 Huffman, J.H., see Sidwell, R.W., 193
 Hughes, G., see Campos, M., 71
 Hughes, T.K., Kaspar, T.A. and Coppenhaver, D.H.
 Synergy of antiviral actions of TNF and IFN- γ : evidence for a major role of TNF-induced IFN- β , 1

- Ikeda, S., Kumazawa, Y., Nishimura, C., Nakatsuka, M., Homma, J.Y., Kiso, M. and Hasegawa, A.
Enhancement of nonspecific resistance to viral infection by chemically synthesized lipid A-subunit analogs with different backbone structures and acyl groups, 167
- Ikeda, S., Sai, K., Nishimura, C. and Yamamoto, A.
Antiherpes activity of the immunomodulator OK-432, a streptococcal preparation, in immunosuppressed mice (Short Communication), 299
- Ilbäck, N.-G., Fohlman, J. and Friman, G.
The anti-inflammatory effect of LS 2616 and poly I:C in coxsackievirus B3 induced murine myocarditis, 129
- Innes, Jr., D.J., see Hayden, F.G., 225
- Ito, M., Sato, A., Hirabayashi, K., Tanabe, F., S., Baba, M., De Clercq, E., Nakashima, H. and Yamamoto, N.
Mechanism of inhibitory effect of glycyrrhizin on replication of human immunodeficiency virus (HIV), 289
- Jeffries, D.J., see Taylor, D.L., 11
- Jenski, L., see Harrison, C.J., 209
- Kaspar, T.A., see Hughes, T.K., 1
- Kende, M., see Burns, III, N.J., 89
- Kini, G.D., see Smee, D.F., 253
- Kiso, M., see Ikeda, S., 167
- Kohl, S., see Bernstein, D.I., 279
- Kong, X.-B., Scheck, A.C., Price, R.W., Vidal, P.M., Fanucchi, M.P., Watanabe, K.A., Fox, J.J. and Chou, T.-C.
Incorporation and metabolism of 2'-fluoro-5-substituted arabinosyl pyrimidines and their selective inhibition of viral DNA synthesis in herpes simplex virus type 1 (HSV-1)-infected and mock-infected Vero cells, 153
- Kucera, P., see Reichman, R.C., 41
- Kumazawa, Y., see Ikeda, S., 167
- Lawman, M.J.P., see Campos, M., 71
- Lenox-Smith, I., see Higgins, P.G., 141
- Levine, P.A., see Hayden, F.G., 225
- Li, X.Q., Gorelik, E., Atchison, R.W., Ovejera, A. and Ho, M.
A new in vivo anti-viral assay using microencapsulated infected cell cultures, 179
- Lie, Y.S., see Fennie, E.H., 27
- Loo, L.S., see Bernstein, D.I., 279
- Low, M.-A.L., see Fennie, E.H., 27
- Mazina, K.E., see Terry, B.J., 235
- McKernan, P.A., see Smee, D.F., 263
- Meerbach, A., see Wutzler, P., 99
- Micha, J.P., see Reichman, R.C., 41
- Mills, S.E., see Hayden, F.G., 225
- Mobberley, M.A., see Taylor, D.L., 11
- Mounts, P., see Reichman, R.C., 41
- Meyers, M.G., Bernstein, D.I., Harrison, C.J. and Stanberry, L.R.
Herpes simplex virus glycoprotein treatment of recurrent genital herpes reduces cervicovaginal virus shedding in guinea pigs, 83
- Nakashima, H., see Ito, M., 289
- Nakatsuka, N., see Ikeda, S., 167
- Nash, R.J., see Taylor, D.L., 11
- Neftel, K.A., see Cottagnoud, P., 59
- Ngan, F., Chang, R.S., Tabba, H.D. and Smith, K.M.
Isolation, purification and partial characterization of an active anti-HIV compound from the Chinese medicinal herb *Viola yedoensis*, 107
- Nishimura, C., see Ikeda, S., 167
- Nishimura, C., see Ikeda, S., 299
- Orsi, N., see Conti, C., 117
- Ovejera, A., see Li, X.Q., 179
- Pifat, D.Y., see Sidwell, R.W., 193
- Pradel, W., see Wutzler, P., 99
- Price, R.W., see Kong, X.-B., 153
- Ramasamy, K., see Smee, D.F., 263
- Reichman, R.C., Micha, J.P., Weck, P.K., Bonnez, W., Wold, D., Whisnant, J.K., Mounts, P., Trofatter, K.D., Kucera, P. and Gall, S.A.
Interferon alpha-n1 (wellferon0 for refractory genital warts: efficacy and tolerance of low dose systemic therapy, 41
- Revankar, G.R., see Smee, D.F., 263
- Robins, R.K., see Smee, D.F., 253
- Robins, R.K., see Smee, D.F., 263
- Ryder, T.A., see Taylor, D.L., 11
- Sai, K., see Ikeda, S., 299
- Sato, A., see Ito, M., 289
- Scheck, A.C., see Kong, X.-B., 153
- Shigeta, S., see Ito, M., 289
- Sidwell, R.W., Huffman, J.H., Barnard, D.L. and Pifat, D.Y.
Effects of ribamidine, a 3-carboxamidine derivative of ribavirin, on experimentally induced Phlebovirus infections, 193
- Sidwell, R.W., see Burns, III, N.J., 89

- Slusarchyk, W.A., see Terry, B.J., 235
- Smee, D.F., Alaghamandan, H.A., Kini, G.D. and Robins, R.K.
Antiviral activity and mode of action of ribavirin 5'-sulfamate against Semliki Forest virus, 253
- Smee, D.F., McKernan, P.A., Alaghamandan, H.A., Frank, K.B., Ramasamy, K., Revankar, G.R. and Robins, R.K.
Antiviral activities of 2'-deoxyribofuranosyl and arabinofuranosyl analogs of sangivamycin against retro- and DNA viruses, 263
- Smith, K.M., see Ngan, F., 107
- Stanberry, L.R., see Myers, M.G., 83
- Stein, M.L., see Conti, C., 117
- Tabba, H.D., see Ngan, F., 107
- Tanabe, F., see Ito, M., 189
- Taylor, D.L., Fellows, L.E., Farrar, G.H., Nash, R.J., Taylor-Robinson, D., Mobberley, M.A., Ryder, T.A., Jeffries, D.J. and Tyms, A.S.
Loss of cytomegalovirus infectivity after treatment with castanospermine or related plant alkaloids correlates with aberrant glycoprotein synthesis, 11
- Taylor-Robinson, D., see Taylor, D.L., 11
- Terry, B.J., Mazina, K.E., Tuomari, A.V., Haffey, M.L., Hagen, M., Feldman, A., Slusarchyk, W.A., Young, M.G., Zahler, R. and Field, A.K.
Broad-spectrum antiviral activity of the acyclic guanosine phosphate (R,S)-HPMPG, 235
- Trofatter, K.F., see Reichman, R.C., 41
- Tuomari, A.V., see Terry, B.J., 235
- Tyms, A.S., see Taylor, D.L., 11
- Tyrrell, D.A.J., see Higgins, P.G., 141
- Ulbricht, A., see Wutzler, P., 99
- Vidal, P.M., see Kong, X.-B., 153
- Voychehovski, T., see Harrison, C.J., 209
- Watanabe, K.A., see Kong, X.-B., 153
- Weck, P.K., see Reichman, R.C., 41
- Whisnant, J.K., see Reichman, R.C., 41
- Wold, D., see Reichman, R.C., 41
- Wutzler, P., Helbig, B., Ulbricht, A., Meerbach, A. and Pradel, W.
Therapeutic effect of pyrophosphate analogues on cutaneous herpes simplex virus type 1 infection in guinea pigs, 99
- Yamamoto, A., see Ikeda, S., 299
- Yamamoto, N., see Ito, M., 289
- Young, M.G., see Terry, B.J., 235
- Zahlerr, R., see Terry, B.J., 235
- Zinkernagel, R.M., see Cottagnoud, P., 59

